Webinar: Life on Ibrance
Tuesday July 27
Ibrance is a CDK4/6 inhbitor that has been publicly funded in New Zealand since April 2020. In this webinar, our expert panel will discuss how Ibrance is used in advanced breast cancer treatment, the practicalities of appointments and tests and how to manage common side effects.
